453 related articles for article (PubMed ID: 30153435)
1. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
2. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
3. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.
Tom MC; Reddy CA; Smile TD; Zhang RX; Ciezki JP; Stephans KL; Mian OY; Klein EA; Campbell S; Ulchaker J; Angermeier K; Tendulkar RD
Brachytherapy; 2020; 19(1):43-50. PubMed ID: 31813740
[TBL] [Abstract][Full Text] [Related]
4. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
5. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
6. Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
8. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
11. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
12. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
[TBL] [Abstract][Full Text] [Related]
14. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
15. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
16. The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment.
Liberman D; Jarosek S; Virnig BA; Chu H; Elliott SP
J Urol; 2016 May; 195(5):1459-1463. PubMed ID: 26682759
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
18. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
19. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
Moschini M; Sharma V; Zattoni F; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Kwon ED; Karnes RJ
J Urol; 2016 Jun; 195(6):1773-8. PubMed ID: 26723866
[TBL] [Abstract][Full Text] [Related]
20. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
